Compare SFST & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFST | AURA |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.5M | 631.6M |
| IPO Year | 2012 | 2021 |
| Metric | SFST | AURA |
|---|---|---|
| Price | $60.27 | $7.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $68.75 | $16.60 |
| AVG Volume (30 Days) | 69.8K | ★ 741.8K |
| Earning Date | 10-20-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.76 | N/A |
| EPS | ★ 3.68 | N/A |
| Revenue | ★ $6,282,000.00 | N/A |
| Revenue This Year | $23.97 | N/A |
| Revenue Next Year | $17.69 | N/A |
| P/E Ratio | $16.45 | ★ N/A |
| Revenue Growth | ★ 12.99 | N/A |
| 52 Week Low | $47.01 | $4.73 |
| 52 Week High | $65.09 | $9.54 |
| Indicator | SFST | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 58.42 |
| Support Level | $58.42 | $6.65 |
| Resistance Level | $63.05 | $7.83 |
| Average True Range (ATR) | 1.68 | 0.42 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 26.06 | 63.68 |
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.